Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24176894 | 0.95 | TYMP (0.42) | TYMPKDM4ETAS1R3TAS1R1TAAR1 | |
| SCHEMBL23827249 | 0.93 | TYMP (0.40) | TYMPKDM4ETAS1R3TAS1R1TAAR1 | |
| SCHEMBL24177253 | 0.88 | TYMP (0.39) | TYMPKDM4ETAS1R3TAS1R1TAAR1 | |
| SCHEMBL23827266 | 0.87 | TYMP (0.48) | TYMPTAAR1HPGDADORA3 | |
| SCHEMBL19362152 | 0.86 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1TAAR1 | |
| SCHEMBL1096942 | 0.86 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1TAAR1 | |
| SCHEMBL24513002 | 0.86 | TYMP (0.45) | TYMPKDM4ETAS1R3TAS1R1TAAR1 | |
| SCHEMBL24177248 | 0.86 | TYMP (0.42) | TYMPTAS1R3TAS1R1HPGDADORA3 | |
| SCHEMBL23827212 | 0.85 | KDM4E (0.35) | TYMPKDM4E | |
| SCHEMBL30898740 | 0.84 | CDK5 (0.36) | TYMPADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-06-24 | — | — | US | claimed |
| CN-119119156-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-12-13 | — | — | CN | claimed |
| EP-4275689-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | claimed |
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-01-06 | — | — | US | claimed |
| EP-3881851-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-09-22 | — | — | EP | claimed |
| US-20250340584-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119119156-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-112996522-B | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| EP-4275690-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4275689-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3881851-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340584-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | POLN, DDX21, MUS81 | TYMP 1322/4885KDM4E 3126/4885TAS1R3 3625/4885 |
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | POLN, DDX21, MUS81 | TYMP 1322/4885KDM4E 3126/4885TAS1R3 3625/4885 |
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | POLN, DDX21, MUS81 | TYMP 1322/4885KDM4E 3126/4885TAS1R3 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.